17 results about "Mycobacterium tuberculosis complex" patented technology

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

The application belongs to the technical field of biological medicine, and particularly relates to a blood Mycobacterium tuberculosis complex free nucleic acid detection kit and a detection method. The application first proposes a kit, wherein a PCR detection reagent group and a CRISPR / Cas12a detection reagent group are arranged in the kit; the PCR detection reagent group comprises a forward primer and a reverse primer which target a complex target; the sequence of the forward primer is overlapped with or complementary to the recognition region of the crRNA sequence, or the sequence of the reverse primer is overlapped with or complementary to the recognition region of the crRNA sequence.

The invention discloses a detection system and method for identifying mycobacteria and drug resistance genes of the mycobacteria based on nanopore sequencing, and relates to the field of biological medicine, the detection system comprises a specific targeted enrichment module, a nanopore sequencing module and a biological information analysis module; the specific targeted enrichment module comprises a probe combination, and the probe combination covers a mycobacterium tuberculosis complex conservative identification gene, species-specific genes of common nontuberculous mycobacteria and mycobacterium leprosy, and full-length or partial sequences of drug resistance related genes in a targeted manner; by utilizing the characteristics of nanopore length reading length and real-time sequencing and a tuberculosis specific targeted enrichment strategy, accurate identification of a mycobacterium tuberculosis complex group, synchronous typing of 42 mycobacteria, analysis of 24 drug-resistant genes, and efficient detection of structural variation and low-abundance heterogeneity drug-resistant mutation are realized, the detection period is shortened, the detection cost is reduced, and the detection efficiency is improved. And a comprehensive and reliable technical basis is provided for accurate diagnosis and treatment of mycobacterium infection.

This application relates to the field of microbial detection technology, specifically to a method for detecting and analyzing the drug resistance of Mycobacterium tuberculosis based on edge computing. The method includes: classifying sequencing data of biological samples based on a metagenomic reference database to obtain a matching dataset aligned to Mycobacterium tuberculosis; extracting representative sequences of each amplified fragment from multiple amplified fragments in the first region based on the matching dataset; and performing a first alignment of the representative sequences of each amplified fragment with a mycobacterium reference database to identify Mycobacterium tuberculosis complexes based on sequence similarity. This method is suitable for operation on edge devices. The method proposed in this application, through process optimization, enables accurate, efficient, and low-cost detection of mycobacteria even with limited computing resources, thereby helping to prevent and control the spread of tuberculosis.

The invention discloses a detection composition and a kit for rapidly detecting the drug resistance of a mycobacterium tuberculosis complex group and rifampicin on site. Based on a novel mycobacterium tuberculosis pretreatment technology and an isothermal amplification technology, a detection scheme for accurately detecting the mycobacterium tuberculosis complex group and rifampicin drug-resistant nucleic acid of the mycobacterium tuberculosis complex group is designed. According to the present invention, the biological enzyme pretreatment splitting action, the RPA isothermal amplification technology and the nucleic acid test strip are combined, the primer and the probe are designed based on the Mycobacterium tuberculosis complex group universal sequence, the new tuberculosis on-site rapid detection method is constructed, the whole detection process can be completed without high temperature heating, the operation is simple, the portability is high, and the cost is low. The kit can become a novel scheme for detecting tuberculosis.

The application belongs to the technical field of molecular biology detection, and particularly relates to a composition for detecting mycobacterium tuberculosis complex and application thereof. The application provides a primer pair and a probe for detecting mycobacterium tuberculosis complex, and simultaneously uses IS6110 and IS1081 genes specific to the mycobacterium tuberculosis complex as detection targets, and introduces a RNase P endogenous internal standard gene fragment, and the primer and the probe are respectively designed according to the conservative sequences of the IS6110 and IS1081 genes of the mycobacterium tuberculosis complex, and the primer and the probe have good accuracy, specificity and sensitivity for detecting the mycobacterium tuberculosis complex. The results of the examples show that the detection accuracy of the primer pair and the probe provided by the application for the mycobacterium tuberculosis complex can reach 100%, and no fluorescence signal is found for detecting other non-mycobacterium tuberculosis species.

This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combinatorial products, kits for identifying Mycobacterium tuberculosis complexes and detecting drug resistance gene mutations, and their applications. This application provides a nucleic acid combinatorial product for tNGS detection of Mycobacterium tuberculosis complexes and related drug resistance genes, comprising at least one pair of primers selected from the nucleotide sequences shown in SEQ ID NO.1 to SEQ ID NO.344. Through optimized primer design, this product significantly improves multiplex PCR amplification efficiency and detection sensitivity. Compared to other NGS technologies such as single-molecule sequencing, this product significantly reduces detection costs while ensuring comprehensive detection, and can complete the entire analysis process from sample processing to result reporting within 24 hours. Furthermore, this nucleic acid combinatorial product also has species identification capabilities, accurately distinguishing Mycobacterium tuberculosis complexes and their species and variant levels, thereby achieving synergistic improvements in detection breadth, cost, timeliness, and identification accuracy.

The invention discloses a mycobacterium tuberculosis complex typing target screening method and application in abundance assessment, and the typing target screening method utilizes a sample data sliding window, a basic group sliding detection edge, subtype inner window regionalization, different subtype unitization regions and other methods. And the candidate region R set presents intra-group aggregation and inter-group difference, so that reliable screening of the typing targets is realized, and the generalization ability is enhanced while the screening efficiency is improved.

To provide a probe that can specifically detect mycobacterium tuberculosis complex.SOLUTION: A probe for detecting mycobacterium tuberculosis complex has an oligonucleotide including (A) 79th to 130th or (B) 277th to 312th base sequence of a specific base sequence, or (C) 37th to 84th base sequence of a specific base sequence or a base sequence of 15 bases or more and 24 bases or less continuous in a base sequence complementary with them, or a base sequence having 1 to 3 bases of difference from the base sequence, where a terminal base of at least one of 5' end and 3' end is cytosine, cytosine of a terminal base of one of 5' end and 3' end has fluorescent dye labeled with oligonucleotide.SELECTED DRAWING: None

The present application relates to the field of biotechnology, in particular to a kind of amplification primer combination and kit for detecting mycobacterium tuberculosis drug resistance gene.The kit is based on nanopore sequencing technology, comprising 20 pairs of primers designed, screened and verified.During detection, these primer mixtures are used, and the DNA of the sample to be tested is amplified by multiplex PCR, each pair of primers amplifies a nucleotide sequence or the entire gene full-length sequence during the reaction, then the high-throughput and long fragment reading characteristics of nanopore sequencing technology are used to obtain the gene sequence, and finally the sample to be tested is determined by bioinformatics analysis.The method of the present application can simultaneously complete the amplification and detection of multiple genes under the same reaction conditions, does not need to culture mycobacterium tuberculosis, can identify mycobacterium tuberculosis complex, and detect multiple drug resistance genes, with the characteristics of multiple indicators, rapid, strong specificity, high sensitivity and the like.

We will provide a new vaccine to prevent TB. [Solution] The present invention relates to a freeze-dried composition comprising a Mycobacterium tuberculosis complex, preferably a clinical isolate of M. tuberculosis, more preferably a clinical isolate of M. tuberculosis (MTBVAC strain), characterized by comprising a PhoP-phenotype due to inactivation by genetic deletion of the Rv0757 gene and a PDIM-phenotype due to deletion of a second gene Rv2930 (fadD26) that inhibits PDIM production, and sucrose and sodium glutamate as stabilizers or excipients. Furthermore, the present invention relates to a reconstituted composition obtained by adding water, preferably sterile water for injection, to the freeze-dried composition. The present invention relates to the composition to be used as a prophylactic agent for people at risk of infection with M. tuberculosis, or as a secondary drug for treating infected tuberculosis patients.

The application discloses a primer probe combination, a kit and application for detecting Nocardia, a mycobacterium tuberculosis complex and mycobacterium, and belongs to the technical field of genetic engineering. The technical problem to be solved is that there is a lack of a nucleic acid detection tool for Nocardia, the mycobacterium tuberculosis complex and mycobacterium in the prior art, which is high in sensitivity, high in specificity and simple in operation. The technical solution is characterized in that the primer probe combination comprises a primer probe for detecting Nocardia, a primer probe for detecting the mycobacterium tuberculosis complex, a primer probe for detecting mycobacterium and a primer probe for detecting an internal standard control. The primer probe combination can simultaneously screen Nocardia, the mycobacterium tuberculosis complex and mycobacterium, quickly and simply confirms pathogenic species, saves time, manpower and reagent cost, and has the advantages of high specificity, a low minimum detection limit and prevention of false negative or false positive results.

The invention belongs to the technical field of immunological detection, and particularly relates to a primer probe composition for detecting drug resistance of mycobacterium tuberculosis complex rifampicin and isoniazide and application of the primer probe composition. A multicolor melting curve method is adopted, rifampicin drug-resistant gene mutation detection is carried out by detecting mutation of drug-resistant determining regions of 507-533 sites of a mycobacterium tuberculosis complex rpoB gene, and isoniazide drug-resistant gene mutation detection is carried out by detecting mutation of ahpC promoter regions, inhA promoter regions and katG315 codons. The drug resistance condition of the detected strain can be judged according to the Tm value of the melting curve. The result of the embodiment shows that the rifampicin drug resistance detection and the isoniazide drug resistance detection realize the detection of mutation of one drug in one tube without separating two tubes, the drug resistance condition of one drug can be independently detected or the drug resistance conditions of two drugs can be detected by the two tubes together according to different conditions during use, the application is flexible, and the cost is low. The application market is wider.

The invention belongs to the technical field of microbial molecule detection, and particularly relates to a multiple LAMP mycobacterium tuberculosis complex group detection method based on a probe method, the LAMP multiple probe method is used for detecting mycobacterium tuberculosis complex flora IS6110 and IS1081 primer groups, the mycobacterium tuberculosis complex flora can be conveniently and rapidly detected at the same time, the positive detection rate of a sputum sample is increased, and the detection time is shortened. Meanwhile, non-specific amplification is weakened, false positive is reduced, the arrangement of the reference gene GAPDH can effectively monitor the sample collection / sample preservation / sample nucleic acid extraction process, and false negative is avoided; the specificity is high, and cross reaction with common strains is avoided. And the sensitivity can reach 10 < 0 > cop i es / u < l >.

The application discloses a primer composition, a kit and application for detecting rifampicin resistance of mycobacterium tuberculosis complex, and belongs to the technical field of biological medicine. The application provides a primer composition for rapidly, sensitively and comprehensively detecting rifampicin resistance of mycobacterium tuberculosis complex, and aims to solve problems of long detection period, low sensitivity of heterogenic resistance detection and incomplete coverage of mutation detection sites in the prior art. The technical scheme of the application is characterized in that a primer composition for detecting rifampicin resistance of mycobacterium tuberculosis complex is provided, at least one group of first primer pairs for specifically amplifying rifampicin resistance related sites is included, a key gene fragment of drug resistance can be efficiently amplified, high-sensitivity detection of heterogenic resistance is realized, and main drug resistance mutation sites are comprehensively covered.

The present invention relates to novel synthetic lipidic alkynylcarbinols, in particular as antibacterial agents, preferably against mycobacteria, and more preferably against species from the Mycobacterium tuberculosis complex, and also to therapeutic uses thereof. The present invention also relates to said compounds for use for the treatment of bacterial infections. The present invention further relates to the discovery of the pharmaceutical mechanism and bioactivity of these novel synthetic lipidic alkynylcarbinols.

The present invention is directed to a protein kinase inhibitor for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, and to corresponding methods of treating tuberculosis. More specifically, the invention relates to the use of protein tyrosine kinase inhibitors such as gefitinib, erlotinib, or imatinib for use in the treatment of tuberculosis, by direct inhibition of the growth of a Mycobacterium tuberculosis complex species, rather than through use in host-directed therapy. Also provided are methods of determining the ability of a protein tyrosine kinase inhibitor to inhibit the growth of a Mycobacterium tuberculosis complex species and methods of identifying a protein tyrosine kinase inhibitor as being potentially effective in the treatment of tuberculosis by direct inhibition of a Mycobacterium tuberculosis complex species.